> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Ticagrelor Trial Misses Primary Endpoint
- URL: https://www.fdaweb.com/ticagrelor-trial-misses-primary-endpoint/
- Published: 2016-03-23T12:00:00.000Z
- Updated: 2026-09-14T20:50:47.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5135166

> AstraZeneca [says](https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-reports-top-line-results-from-the-brilinta-socrates-trial-in-stroke-23032016.html?ref=fdaweb.com) that the SOCRATES trial that assessed the efficacy of Brilinta/Brilique (ticagrelor) compared with aspirin in patients with acute ischemic stroke or transient ischemic attack missed its primary endpoint of time to first occurrence of any event from the composite of stroke, heart attack, and death. “Fewer events were observed on Brilinta/Brilique versus the comparator in the overall trial population, but the trend did not reach statistical significance,” the company says.  
>  
> Brilinta/Brilique is described as a direct-acting P2Y12 receptor antagonist that works by inhibiting platelet activation and has been shown to reduce the rate of thrombotic cardiovascular events. Its 90mg dose is indicated to reduce the rate of thrombotic cardiovascular events in patients with unstable angina, non-ST-elevation myocardial infarction, or ST-elevation myocardial infarction. A 60mg dose is indicated for treating patients who have suffered a heart attack at least one year prior and are at high risk for developing a further atherothrombotic event.  
>  
> The drug, AstraZeneca says, has been shown to reduce the rate of a combined endpoint of cardiovascular death, heart attack, or stroke compared to clopidogrel. It says the difference between treatments was driven by cardiovascular death and heart attack, with no difference in stroke. In patients treated with percutaneous coronary intervention, it reportedly also reduces the rate of stent thrombosis.